In our 11th annual analysis of Series A financings, we look at five sub-species of A round investors, their habits, habitats, and behaviors during 2014.
So you are looking for an A round in 2015? What are your chances and how should you maximize them? What can you learn from the A-List class of 2014?
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
There was a reduction in the rate of expansion of the pharma pipeline last year but 2024 also saw another welcome increase in the number of drug candidates in Phase III following years of stagnation.
Results from a China Phase III trial show the potential of RemeGen's fusion protein telitacicept in generalized myasthenia gravis. But study design differences make direct comparisons with argenx's FcRn inhibitor Vyvgart challenging.
Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.
Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.
ICER’s new white paper pointed to estimates that the GLP-1 drugs may result in more than $100bn in annual spending, highlighting the need to rein in costs.
The rollout of Trump’s tariff plan has been a policy whiplash, but despite a 90-day pause on tariffs, it appears the US president is still holding a grudge with industry over drug pricing.
European pharma leaders want to see a deal so that no tariffs are imposed on medicines – but they also want the European Union to urgently rethink its sector policies that they believe will lead to massive investment loss.
